Zantac ordered off the shelves by FDA due to Cancer causing NDMA

By Joe Messa

Apr 01

The U.S. Food and Drug Administration (FDA) issued a press release today requesting that manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately.

This comes months after the FDA announced its initial warning regarding ranitidine medications (brand name ZANTAC) and the possible presence of a contaminant known as N-Nitrosodimethylamine (NDMA). NDMA is a known carcinogen (a substance than could cause cancer) and the FDA has determined that the NDMA in some ranitidine products can increase 1) over time, and 2) when stored at higher than room temperature. This increase can result in dangerous levels of exposure to consumers. As a result of this immediate market withdrawal, Zantac and all generic ranitidine products are no longer available for prescription or OTC use.

The FDA urges all consumers to discontinue use of ZANTAC or other ranitidine drugs IMMEDIATELY. In light of the COVID-19 pandemic and quarantine measures across the nation, the FDA recommends that patients and consumers follow specific disposal instructions in the medication guide or package insert for safe at-home disposal, instead of bringing their medicines to a drug take-back location.

Dangers of NDMA and Zantac use

NDMA exposure has been linked to a number of cancers, including, but not limited to the following:

  • Stomach
  • Small intestine
  • Colorectal
  • Esophageal
  • Liver
  • Prostate (early onset)
  • Pancreatic
  • leukemia
  • Non-Hodgkin’s Lymphoma
  • Multiple Myeloma

If you have been prescribed or purchased name brand or generic ranitidine and have been diagnosed with one of the above-named cancers, it is likely that you have a claim against the makers of Zantac. Numerous lawsuits have already been filed nationwide and more are expected to follow. If you are interested in filing a claim and want to qualify as a plaintiff, you must;

  1. Prove that you used the medication. If you took, or are taking Zantac, or another form of ranitidine, you should request a copy of your pharmacy records to document your usage; and
  2. Show that you have an injury, meaning that you have been diagnosed with at least one of the cancers linked to NDMA exposure; and

To request a free consultation to determine whether you, a friend, or family member may be entitled to financial compensation in this lawsuit, contact Messa & Associates by calling 877-637-7252 or submitting an inquiry online.

Skip the phone call and sign up as a plaintiff here: ZANTAC Lawsuit – Client Agreement


About the Author

Joseph L. Messa, Jr. is the founding partner of Messa & Associates, P.C. He is an AV-rated attorney (highest rating available), listed in the Bar Register of Preeminent Lawyers. Read More